SELECT: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor–mutant non–small-cell lung cancer
NA Pennell, JW Neal, JE Chaft, CG Azzoli… - Journal of Clinical …, 2019 - ascopubs.org
… 56 of them having received adjuvant erlotinib. The reported 2-… percentage of patients with
stage II and III disease in the treated … During the conduct of our study, two phase III trials were …
stage II and III disease in the treated … During the conduct of our study, two phase III trials were …
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated …
K Nakagawa, EB Garon, T Seto, M Nishio, S Ponce Aix… - 2019 - ascopubs.org
9000 Background: Dual blockade of EGFR and VEGFR pathways in EGFRm NSCLC augments
anti-tumor efficacy versus (v) EGFR inhibition alone. RELAY (NCT02411448) evaluated …
anti-tumor efficacy versus (v) EGFR inhibition alone. RELAY (NCT02411448) evaluated …
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study
YL Wu, JH Kim, K Park, A Zaatar, G Klingelschmitt… - Lung cancer, 2012 - Elsevier
… In the overall population of the phase III SATURN study of erlotinib maintenance therapy,
erlotinib significantly improved PFS and OS compared with placebo (HR = 0.71 and 0.81, …
erlotinib significantly improved PFS and OS compared with placebo (HR = 0.71 and 0.81, …
[HTML][HTML] A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer
… activity in prior early phase studies in patients with EGFR-mutated lung cancer with disease
… was not superior to a first-generation tyrosine kinase inhibitor in the current phase III study. …
… was not superior to a first-generation tyrosine kinase inhibitor in the current phase III study. …
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
… chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients
with advanced non-small-cell lung cancer. We undertook FASTACT-2, a phase 3 study in …
with advanced non-small-cell lung cancer. We undertook FASTACT-2, a phase 3 study in …
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed …
…, SR Wijayawardana, K Turner, GJ Oakley III… - Frontiers in …, 2020 - frontiersin.org
… -label trial of abemaciclib versus erlotinib in patients with stage IV NSCLC and a detectable
… patients (3:2) received either 200 mg abemaciclib twice daily or 150 mg erlotinib once daily …
… patients (3:2) received either 200 mg abemaciclib twice daily or 150 mg erlotinib once daily …
A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)
…, Hokkaido Lung Cancer Clinical Study Group - Cancer chemotherapy …, 2017 - Springer
… erlotinib as third-line compared with those who received erlotinib as second-line [13, 14].
Thus, … as a third- or fourth-line therapy for wild-type EGFR NSCLC for a future phase III study. …
Thus, … as a third- or fourth-line therapy for wild-type EGFR NSCLC for a future phase III study. …
… III study of combining erlotinib with bevacizumab and panitumumab versus erlotinib alone as second-line therapy for Chinese patients with non-small-cell lung cancer
Y Wang, H Wang, Y Jiang, Y Zhang, X Wang - Biomedicine & …, 2017 - Elsevier
… In this phase III clinical study, we assessed the clinical outcomes of combining erlotinib
with … as second-line chemotherapy for patients with non-small-cell lung cancer (NSCLC). …
with … as second-line chemotherapy for patients with non-small-cell lung cancer (NSCLC). …
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non–small-cell lung cancer
DR Spigel, HA Burris III, FA Greco… - Journal of clinical …, 2011 - ascopubs.org
… (BETA) phase III trial, bevacizumab was added to erlotinib in patients with relapsed NSCLC.
Although PFS was improved with the combination compared with erlotinib alone (HR, 0.62; …
Although PFS was improved with the combination compared with erlotinib alone (HR, 0.62; …
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non–small-cell lung cancer: results of a phase I/II trial
MA Socinski, TE Stinchcombe, DT Moore… - Journal of clinical …, 2012 - ascopubs.org
… In summary, the use of bevacizumab and erlotinib is not recommended in the setting of
combined-modality therapy in stage III NSCLC. This recommendation is based on the lack of an …
combined-modality therapy in stage III NSCLC. This recommendation is based on the lack of an …